Therefore, treatment strategies should be based on patient-related factors (age, PS, comorbidity, and preferences) and disease-related factors (tumor aggressiveness, disease burden, presence of symptoms, RAS/BRAF mutational status, and MSI-H). The gene discussed is BRAF; the disease is neoplasm.